NeuroSense Announces Significant Survival Benefit with PrimeC in ALS

New data shows 65% reduction in risk of death and over 14-month median survival improvement.

Published on Feb. 21, 2026

Got story updates? Submit your updates here. ›

NeuroSense Therapeutics, a biotechnology company focused on neurodegenerative diseases, announced positive long-term survival data from its Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS). The updated analysis demonstrated a statistically significant 65% reduction in the risk of death and over 14-month improvement in median survival for patients treated with PrimeC compared to placebo.

Why it matters

These findings further validate the potential of PrimeC as a disease-modifying therapy for ALS, a devastating neurodegenerative disease with limited effective treatment options. The substantial survival benefit could have a major impact on the lives of ALS patients and their families.

The details

The PARADIGM Phase 2b trial was a randomized, double-blind, placebo-controlled study in 68 ALS patients. Patients who received PrimeC continuously during both the double-blind and open-label phases achieved a median survival of 36.3 months, compared to 21.4 months for those initially assigned to placebo. This represents a 70% increase in median survival. The survival benefit was statistically significant and sustained over time.

  • The PARADIGM Phase 2b trial was previously completed.
  • The new long-term survival data is based on extended follow-up of the trial participants.

The players

NeuroSense Therapeutics Ltd.

A late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases.

PrimeC

NeuroSense's lead drug candidate, a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib.

Alon Ben-Noon

The CEO of NeuroSense.

Got photos? Submit your photos here. ›

What they’re saying

“The long-term survival data further validate the magnitude and durability of PrimeC's effect in ALS and reinforce its potential as a disease-modifying therapy.”

— Alon Ben-Noon, CEO of NeuroSense (PRNewswire)

What’s next

NeuroSense continues to engage with regulatory authorities regarding the advancement of PrimeC into pivotal late-stage development.

The takeaway

The substantial survival benefit demonstrated by PrimeC in this ALS study represents a major potential breakthrough for a disease with limited treatment options, and could significantly improve the lives of ALS patients if the findings are replicated in future clinical trials.